Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2026 Jun 16;16:27588. doi: 10.1038/s41598-026-58425-x

Photodynamic therapy enhances dacarbazine sensitivity of melanoma cells by induction of apoptosis and downregulation of PI3K/AKT signaling pathway

Masoumeh Hajizadeh 1, Mohammad Amin Doustvandi 1,✉, Fateme Mohammadnejad 1, Nadia Allahyarzadeh Khiabani 1, Shima Alizadeh Nobari 1,2, Seyedeh Samaneh Shahriar Oskouei 1, Habib Tajalli 3,4, Elham Mehdizadehfar 1, Behzad Baradaran 1,✉
PMCID: PMC13538685  PMID: 42303749

Abstract

Dacarbazine (DTIC) is a crucial drug for treating melanoma, but resistance to it poses a significant challenge to effective chemotherapy. Photodynamic therapy (PDT), a minimally invasive, repeatable, and highly selective anti-cancer treatment, has shown promise in recent studies as a potent modulator of chemotherapy sensitivity in different cancerous cells. This investigation aims to explore the effect of photodynamic treatment on the DTIC sensitivity of melanoma cells. The SKMEL-3 melanoma cells were treated with PDT and DTIC, separately or in combination. The toxicity consequences of these treatments were studied using MTT test. This assay was used to analyze the cytotoxic effects of these treatments, and increased DTIC sensitivity was observed in SK-MEL-3 cells following pre-treatment with PDT. Additionally, flow cytometry analysis showed sub-G1 phase cell cycle arrest and increased apoptosis in all treatment groups. Alterations in the expression levels of caspases (3, 8, 9) and Bcl-2 genes further confirmed that apoptosis was more pronounced in the combination group. Moreover, combining PDT with DTIC significantly downregulated the expression of PI3K, AKT, and mTOR, while upregulating PTEN. Our data suggest that all mentioned treatments significantly reduce cell migration by downregulating MMP-2 and MMP-9 and decrease clonogenicity by downregulating SOX2 and OCT4 in SK-MEL-3 cells, with these effects being more evident after combination treatment. In conclusion, our findings highlight the potential of PDT pre-treatment to enhance DTIC sensitivity in SK-MEL-3 cells and suggest that the combination therapy is a promising strategy for further research in melanoma treatment.

Keywords: Melanoma, Chemotherapy, Dacarbazine sensitivity, Photodynamic therapy, Apoptosis, PI3K/AKT signaling pathway

Subject terms: Cancer, Cell biology, Oncology

Introduction

Melanoma is the most malignant and lethal type of skin cancer, which is caused by a malignant transformation in melanocytic cells of the skin. Unfortunately, in the past decades, the incidence of melanoma has increased significantly, representing around 3% of all skin cancers1–3. Despite considerable developments in the traditional therapeutic approaches for melanoma, including surgical excision, radiotherapy, and chemotherapy, the ten-year survival rates of patients with metastatic melanoma are still less than 10%4–6.

Different driver mutations have been recognized in melanoma cells, in particular in the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and phosphoinositide 3-kinase/AK strain transforming kinase (PI3K/AKT) pathways. Approximately 50 to 70% of melanoma cases have the BRAF (v-RAF murine sarcoma viral oncogene homolog B1) V600 mutation7.

In recent years, novel therapeutic approaches have been developed for metastatic melanoma. As a hopeful targeted therapy, Vemurafenib (a BRAFV600E inhibitor) was developed (with a response rate of ~ 50%) for specially targeted mutated melanoma cell proteins. Nevertheless, most melanomas recur within a few months8. Also, nivolumab and ipilimumab (a PD-1 inhibitor and a CTLA-4 inhibitor, respectively), as immune checkpoint inhibitors, were developed to increase the endogenous anti-tumor immune response. However, nivolumab and ipilimumab are successful in only a subpopulation of melanoma patients, with a primary resistance higher than 50% and an improvement of acquired resistance in initial responders9. The high percentage of heterogeneity of melanomas is responsible for the lack of effective treatment options, thus causing the growing need for the development of traditional and hopeful therapeutic approaches. In addition, melanoma cell heterogeneity is correlated to the presence of distinct subpopulations of melanoma cells in the tumor bulk, thus resulting in chemotherapeutic drug resistance10.

In 1975, the Food and Drug Administration (FDA) granted approval to dacarbazine (DTIC), also known as dimethyltriazeno-imidazole carboxamide, making it the first chemotherapy drug authorized by the FDA for the treatment of melanoma11. Unfortunately, DTIC no longer works as the standard of treatment for metastatic melanoma owing to its 1-year survival rate of 27%. Furthermore, none of the chemotherapeutic drugs have been more effective in survival rates, and none have been less toxic than DTIC. Consequently, chemotherapeutic drug use for metastatic melanoma has decreased over time12. Therefore, therapies that improve the response rates of melanoma cells toward DTIC could be highly effective and specific at increasing the effectiveness of DTIC-based chemotherapy10.

Numerous therapeutic approaches have been combined with DTIC to enhance the effectiveness and reverse the resistance13. Photodynamic therapy (PDT), as a hopeful therapeutic approach, has the potential to be such a therapy. PDT is an insignificantly invasive anti-cancer treatment; it involves systemic or topical administration of a photoactive compound (photosensitizer) and elucidation of the tumor cells in the presence of molecular oxygen with harmless visible light. Photosensitizer molecules absorb light of the appropriate wavelength, initiating the activation processes leading to the formation of reactive oxygen species (ROS) and the selective destruction of inappropriate cells14–16.

Interestingly, PDT can be administered either after or before chemotherapy without compromising this therapeutic modality17. Accordingly, combining chemotherapeutic drugs with PDT has received attention as a hopeful approach to enhance the effectiveness of chemotherapy drugs for different cancers. Such a combined therapeutic procedure not only improves the chemotherapy effectiveness but also requires lower doses of the chemotherapy drugs, thus decreasing the side effects and neutralizing the development of drug resistance18,19.

Numerous cellular and molecular mechanisms may be accountable for the higher effectiveness of a combined chemotherapeutic drug-PDT approach, such as induction of apoptosis and ROS production, reduction or inhibition of cell migration and colony formation ability, cell-cycle arrest, and re-regulation of different signaling pathways, etc12,17,20. These mechanisms make the cancer cells more sensitive to chemotherapy drugs. Therefore, we conjectured that PDT might increase melanoma cells’ sensitivity to DTIC via the PI3K/AKT signaling pathway to enhance apoptosis. In this regard, the present study ascertained the impact of pre-treatment with PDT on the DTIC-sensitivity of melanoma cells.

Materials and methods

Cell culture

The SKMEL-3 (human melanoma cell line) was obtained from the Pasteur Institute (Tehran, Iran). These cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Gibco, USA) and 1% antibiotics (penicillin /streptomycin, Gibco, USA). Later, cells were preserved in the incubator at 37 °C, 5% CO2, and 95% humidity.

Cytotoxicity of Zinc phthalocyanine (ZnPc)-PDT, DTIC, and DTIC with ZnPc-PDT on melanoma cell line SKMEL-3

To investigate the cytotoxic effects triggered by each of the ZnPc-PDT, DTIC, and DTIC with ZnPc-PDT treatments, (1) in 96-well plates, SKMEL-3 cells were seeded (for 24 h maintained in an incubator) and treated for 24 h in a dark environment with various ZnPc concentrations (0.00001–5 µg/mL), the initial stock solution comprising 2% (v/v) DMSO (dimethyl sulfoxide) in RPMI 1640, in the medium supplemented with 10% FBS. Afterward, irradiation was carried out with a diode laser for ~ 50 s (at 675 nm wavelength with 80 mW output power and 20 J/cm2 energy density; Table 1). Next, SKMEL-3 cells were kept in the dark situation for 24 h. (2) To study the cytotoxic effects of the DTIC on SKMEL-3, the same cell culture protocol described above was applied. After that, the SKMEL-3 cells were treated with DTIC at different concentrations (0.0001–100 µg/mL) for 24 h. (3) To study the effects of pre-treatment of ZnPc-PDT on increased sensitivity of melanoma cells towards DTIC, initially, the SKMEL-3 cells were incubated with the IC25 value of ZnPc-PDT, subsequently, the melanoma cells were treated with DTIC (0.0001–100 µg/mL) for 24 h. The IC25 concentration of ZnPc-PDT was chosen for combination experiments with DTIC because it induces a moderate photodynamic effect while maintaining sufficient cell viability. This sub-lethal dose allows evaluation of potential synergistic or sensitizing effects with DTIC without causing excessive cytotoxicity from PDT alone.

Table 1.

Primers sequences.

Gene name Primer sequence
GAPDH

Forward: 5´ CCTCGTCCCGTAGACAAAA 3´

Reverse: 5´ AATCTCCACTTTGCCACTG 3´

Bcl2

Forward: 5´ CCTGTGGATGACTGAGTACC 3´

Reverse: 5´ GAGACAGCCAGGAGAAATCA 3´

Caspase − 9

Forward: 5´ CCGGAATCCTGCTTGGGTATC 3´

Reverse: 5´ CATCGGTGCATTTGGCATGTA 3´

Caspase − 8

Forward: 5´ GGTCTGAAGGCTGGTTGTTC 3´

Reverse: 5´ AATCTCAATATTCCCAAGGTTCAAG 3´

Caspase − 3

Forward: 5´ TGTCATCTCGCTCTGGTACG 3´

Reverse: 5´ AAATGACCCCTTCATCACCA 3´

MMP2

Forward: 5´ GCCCTCCTGGGAATGAAGCAC 3´

Reverse: 5´ GCATTGCCTCTGGACAACACA 3´

MMP9

Forward: 5´ GGTTCTTCTGCGCTACTGCTG 3´

Reverse: 5´ GTCGTAGGGCTGCTGGAAGG 3´

PI3K

Forward: 5´ GAAGCACCTGAATAGGCAAGTCG 3´

Reverse: 5´ GAGCATCCATGAAATCTGGTCGC 3´

AKT

Forward: 5´ GCTGCACAAACGAGGGGAG 3´

Reverse: 5´ CCGCTCCGTCTTCATCAGCT 3´

mTOR

Forward: 5´AGATGCTTGGAACCGGACCTG 3´

Reverse: 5´ CCAAGATGCCACCTTTCCTCTC 3´

PTEN

Forward: 5´ TGATGTAGTAAGTTGTGCTGAAAGA 3´

Reverse: 5´ GCACATATCATTACACCAGTTCGT 3´

OCT4

Forward: 5´ GGGCTCTTTGTCCACTTTGT 3´

Reverse: 5´ GGCATGCATACACACAAACAC 3´

SOX2

Forward: 5´ACATGTGAGGGCCGGACAGC 3´

Reverse: 5´TTGCGTGAGTGTGGATGGGATTGG 3´

After a day following each of the three treatment methods previously described, the cytotoxicity of each treatment was determined by using the MTT assay, which was carried out by adding 50 µl MTT solution (2 mg/ml) and 100 µl complete medium. Following a 4-hour maintenance period at 37 °C in a dark environment, 100 µl of DMSO was used to swap the medium. To measure the optical density (OD) at 570 nm, an ELISA reader (SunriseTM, Tecan, Switzerland) was used. For each treatment approach, three-independent experiments were utilized.

Annexin V and PI assay

Determining the level of necrotic/apoptotic cells was done using flow cytometry (MacsQuant10Analyser, Miltenyi Biotech, Germany) analysis. Briefly, each well was seeded at a density of 12 × 104 melanoma cells and treated as mentioned above. We followed the manufacturer’s instructions to stain the different treatment groups and used an AnnexinV/PI staining kit (EXBIO, Czech Republic). Propidium-iodide (PI) and binding buffer were added to the melanoma cells for the staining process annexin-V. Subsequently, cells were kept in a dark environment at 25˚C for 15 min. Finally, the apoptosis and necrosis levels were calculated via a flow cytometer.

Wound healing test

A wound-healing assay was utilized to investigate the cell migration capability of melanoma cells. The cells at a density of 12 × 104 were seeded in each well and maintained in an incubator. When the cells reached the confluency of ~ 70–80%, the bottom of each well was scratched using a sterile yellow micropipette tip, and then the cells were treated as mentioned above. Images of scratched areas were captured at 0, 12, and 24 h after treatment using an OPTIKA (Italy) microscope, and the migration capability was examined.

Colony-formation assay

For in vitro assays of colony formation capability of melanoma cells, the cells were seeded into 12-well plates (500 cells per well), and these cells were kept in the incubator to reach ~ 50–60 cells per colony. Afterwards, the cells were treated and maintained in the incubator. After that, a crystal violet staining solution was used to stain each treatment group. Eventually, each treatment group was photographed using an OPTIKA (Italy) microscope. Ultimately, the number of colonies for each group were counted using ImageJ software (NIH, MD).

Cell cycle assay

Cell cycle investigation was carried out in this study using propidium iodide (PI). After the mentioned treatments, the melanoma cells were harvested and fixed with ethanol (70%) at -20 ◦C for 24 h. The next step was a 30-min incubation with 1 mg/ml of RNase A. After incubation, treated cells were stained with PI solution (20 mg/ml) for 10 min. Finally, the cells were analyzed using a flow cytometer (Miltenyi Biotech, Germany).

QRT-PCR analysis

After treatments, total RNA (all cells) was extracted following the manufacturer’s instructions using the RiboEX reagent (GeneAll, South Korea). Also, each RNA sample’s quantity and quality were determined using NanoDrop (DeNovix DS-11 FX, USA). After that, cDNA was synthesized for each sample using the cDNA synthesis reagent (Addbio, South Korea), in accordance with the manufacturer’s protocol. QRT-PCR analysis was prepared using a SYBR Green PCR master mix (Smobio Technology Inc., Taiwan) protocol in the light cycler system (ABI, USA). The GAPDH gene was used as a reference (an internal control) for examined genes. The 2 − ΔΔCt cycle threshold approach was used to standardize the relative expression levels of the genes that were normalized with GAPDH. Sequences of utilized primers are presented in Table 1.

Statistical analysis

The data are presented as means ± SD. All statistical analyses were performed using GraphPad Prism 8 (CA, USA). Unpaired t-tests, one-way ANOVA, and two-way ANOVA were used to determine statistically significant differences between groups. Where significant differences were detected by ANOVA, Dunnett’s post-hoc test was applied to compare each treatment group with the control group. A p-value of less than 0.05 was considered statistically significant.

Results

Pre-treatment with ZnPc-PDT significantly increased the sensitivity of melanoma cells toward DTIC

As shown in Fig. 1A and B, the results of cytotoxicity evaluation of DTIC (alone) and ZnPc-PDT (alone) led to the initiation of concentration-dependent cytotoxicity in melanoma cells. The IC25 and IC50 values of ZnPc in 20 J/cm2 energy density of laser were 0.002 ± 0.01 µg/mL and 0.065 ± 0.01 µg/mL, respectively. Besides, the IC50 value of DTIC was 47.14 ± 0.01 µg/mL. Furthermore, our findings indicated that the laser irradiation alone (without ZnPc; not shown in the data) and different concentrations of ZnPc without laser irradiation (Fig. 1A) had no observable toxic effects on melanoma cells.

Fig. 1.

Fig. 1

The cell viability of ZnPc, ZnPc-PDT, DTIC, and combination treatment 24 h after treatments by MTT assay: (A) The cell viability of different concentrations of ZnPc (0.00001–5 µg/mL) without or with laser source (20 J/cm2); (B) The cell viability of the different concentrations of DTIC (0.0001–100 µg/mL) without or with ZnPc-PDT (0.002 ± 0.01 µg/mL; 20 J/cm2); (C) The CI of the combined treatment of ZnPc-PDT and DTIC was calculated based on the Chou-Talalay method. Results are presented as mean ± SD (n = 3) (**** P-value < 0.0001 compared to control group).

The IC25 value of ZnPc-PDT was selected for the combination treatment, as the IC50 value of ZnPc-PDT provided high toxicity with DTIC. Similarly, the cytotoxic effects of combination treatment on melanoma cells were determined and set as a new IC50 value for DTIC (4.23 ± 0.01 µg/mL; Fig. 1B). To investigate the effect of combined ZnPc-PDT and DTIC cytotoxic effect on SKMEL-3 cells, the combination index (CI) was calculated according to the Chou-Talalay method (Fig. 1C). CI revealed that the combination of ZnPc-PDT and DTIC produced synergistic effects across a wide concentration range of DTIC (CI < 1.0).

Combination treatment of ZnPc-PDT with DTIC led to a significant enhancement in the apoptotic response of melanoma cells

To assess the levels of apoptotic cells generated by DTIC, ZnPc-PDT, and DTIC combined with ZnPc-PDT, we used the ApoFlowEx® FITC Kit. Apoptotic cells in the DTIC (alone) and ZnPc-PDT (alone) were detected, meaningfully higher in the DTIC combined with the ZnPc-PDT group. As shown in Fig. 2A and a, we can observe that DTIC combined with ZnPc-PDT can trigger meaningfully high levels of apoptotic cells and keep the necrotic cell levels unimportant.

Fig. 2.

Fig. 2

DTIC (4.23 ± 0.01 µg/mL), ZnPc-PDT (0.002 ± 0.01 µg/mL; 20 J/cm2), and DTIC (4.23 ± 0.01 µg/mL) combined with ZnPc-PDT (0.002 ± 0.01 µg/mL; 20 J/cm2)-induced apoptotic cell death (A, a) apoptotic and necrotic cells were determined by using flow cytometry at 24 h after treatments. (B) Caspase-9, Caspase-8, Caspase-3, and Bcl-2 gene expression in DTIC, ZnPc-PDT, and DTIC combined with ZnPc-PDT were determined using qRT-PCR at 24 h after treatments. Results are presented as mean ± SD (n = 3). One-way ANOVA test was used; ** P-value < 0.01, *** P-value < 0.001, and **** P-value < 0.0001 compared to control group.

We also studied the molecular pathways responsible for the induction of apoptotic cells. For this purpose, 24 h after DTIC, ZnPc-PDT, and DTIC combined with ZnPc-PDT the gene expression changes of caspase-8, -9, and − 3 were investigated on the melanoma cells. As shown in Fig. 2B, following DTIC, ZnPc-PDT, and DTIC combined with ZnPc-PDT treatments, we observed that the expression levels of caspase-9 and − 3 were meaningfully increased in melanoma cells compared to control cells. Furthermore, we observed that caspase-8 expression levels in all groups were significantly increased compared to the control group. Furthermore, we investigated the expression levels of the Bcl-2 gene. As evaluated, we saw that the expression of the Bcl-2 gene in all studied groups was meaningfully decreased compared to the control group.

Combination treatment of ZnPc-PDT with DTIC caused a considerable reduction in cell migratory capabilities of melanoma cells and expression of related genes

To further investigate the capacity of DTIC, ZnPc-PDT, and DTIC combined with ZnPc-PDT, we also evaluated their effects on the cell migration capability of melanoma cells. We observed that melanoma cells in the control and DTIC (alone) groups almost completely covered the wound gap 24 h after treatment (Fig. 3A). We also examined whether ZnPc-PDT has inhibitory potential on the cell migration capability of melanoma cells. Melanoma cells treated with ZnPc-PDT have a decreased capacity for cell migration compared to control cells. We further investigated the cell migration ability after treatment with DTIC combined with ZnPc-PDT. Interestingly, the wound healing assay results revealed that DTIC combined with ZnPc-PDT has a higher potential to suppress melanoma cell migration capability.

Fig. 3.

Fig. 3

The impacts of DTIC (4.23 ± 0.01 µg/mL), ZnPc-PDT (0.002 ± 0.01 µg/mL; 20 J/cm2), and DTIC (4.23 ± 0.01 µg/mL) combined with ZnPc-PDT (0.002 ± 0.01 µg/mL; 20 J/cm2) on cell migration capability of melanoma cells at 24 h after treatment. (A) After different treatments, the melanoma cells were scratched, and scratch gaps were focused by an inverted microscope (0–24 h). (B) The effect of DTIC, ZnPc-PDT, and DTIC combined with ZnPc-PDT on MMP-2 and MMP-9 genes 24 h after treatment in melanoma cells. Results are presented as mean ± SD (n = 3). One-way ANOVA test was used; ** P-value < 0.01, *** P-value < 0.001, and **** P-value < 0.0001 compared to the control group.

To offer more convincing evidence, we evaluated the gene expression of MMP-2 and MMP-9, which may be associated with melanoma cell migration capability. As revealed in our qRT-PCR results in Fig. 3B, in comparison to control cells, the MMP-2 gene expression was meaningfully reduced in DTIC, ZnPc-PDT, and DTIC combined with ZnPc-PDT groups, which was more decreased in the combination group than in the DTIC alone. Also, in comparison to control cells, the MMP-9 gene expression was significantly reduced in DTIC, ZnPc-PDT, and DTIC combined with ZnPc-PDT groups, which was more decreased in the combination group than in the DTIC (alone) and ZnPc-PDT (alone) (Fig. 3B).

Combination treatment of ZnPc-PDT with DTIC resulted in a considerable reduction in the colony formation capability of melanoma cells

In the present study, we carried out the colony formation assay to investigate if individual or/and combined treatment of DTIC and ZnPc-PDT could reduce colony formation capability. The colony numbers were dampened after ZnPc-PDT and DTIC single usage, compared to the control group. In contrast, the colony numbers were observably low in the DTIC combined with the ZnPc-PDT group (Fig. 4A).

Fig. 4.

Fig. 4

The effects of DTIC (4.23 ± 0.01 µg/mL), ZnPc-PDT (0.002 ± 0.01 µg/mL; 20 J/cm2), and DTIC (4.23 ± 0.01 µg/mL) combined with ZnPc-PDT (0.002 ± 0.01 µg/mL; 20 J/cm2) on colony formation capability of melanoma cells at 24 h after treatment. (A, a) The colony numbers were significantly decreased in the combination group. (B) The effect of DTIC, ZnPc-PDT, and DTIC combined with ZnPc-PDT on SOX2 and OCT4 genes 24 h after treatment in melanoma cells. Results are presented as mean ± SD (n = 3). One-way ANOVA test was used; ** P-value < 0.01, *** P-value < 0.001, and **** P-value < 0.0001 compared to the control group.

Also, to support the decrease of colony formation capability of melanoma cells following combination treatment of DTIC with ZnPc-PDT at the molecular level, we studied the expression levels of related genes. As shown in Fig. 4B, qRT-PCR analyses revealed that SOX2 and OCT4 gene mRNA expression levels were meaningfully decreased in DTIC combined with ZnPc-PDT compared with the DTIC (alone) and ZnPc-PDT (alone).

Combination treatment of ZnPc-PDT with DTIC led to a significant arrestment in the subG1 phase of the cell cycle of melanoma cells

To determine whether the DTIC, ZnPc-PDT, and DTIC combined with ZnPc-PDT affect cell cycle distribution, we studied the cell cycle distribution of melanoma cells after the mentioned treatments. As shown in Fig. 5A and B, flow cytometry results showed that DTIC reduced the population of the subG1 phase of the cell cycle from 0.78% to 4.24%. Also, treatment with ZnPc-PDT increases the subG1 phase cell cycle population from 0.78% to 8.46%. Interestingly, DTIC combined with ZnPc-PDT augmented the sub-population of melanoma cells in the subG1 phase by 0.78% to 23.60%. It is revealed that the combination treatment can augment the percentage of melanoma cells in the subG1 phase.

Fig. 5.

Fig. 5

The effects of DTIC (4.23 ± 0.01 µg/mL), ZnPc-PDT (0.002 ± 0.01 µg/mL; 20 J/cm2), and DTIC (4.23 ± 0.01 µg/mL) combined with ZnPc-PDT (0.002 ± 0.01 µg/mL; 20 J/cm2) on cell cycle distribution of melanoma cells at 24 h after treatment. (A) The distribution of the cell cycle was assessed using flow cytometry 24 h after treatment. (B) Results are presented as mean ± SD (n = 3). A two-way ANOVA test was used; ** P-value < 0.01, **** P-value < 0.0001 compared to the control group.

Combination treatment of ZnPc-PDT with DTIC caused to a considerable reduction of the pathway mediated by PI3K/AKT in melanoma cell lines

To elucidate the possible effect of DTIC combined with ZnPc-PDT on the PI3K/AKT signaling pathway in melanoma cells, we also studied the expression levels of PI3K/AKT pathway-related genes in treated cells with DTIC (alone), ZnPc-PDT (alone), and DTIC combined with ZnPc-PDT by qRT-PCR.

As offered in Fig. 6, the downregulated gene expression levels of PI3K, AKT, and mTOR were observed in melanoma cells after ZnPc-PDT (alone) and DTIC combined with ZnPc-PDT groups, especially in the combination group. However, the PI3K, AKT, and mTOR gene expression levels were upregulated in the DTIC (alone) group. Furthermore, we observed that all mentioned treatments resulted in increased gene expression levels of PTEN, which was more evident after combination treatment (Fig. 6).

Fig. 6.

Fig. 6

Effects of DTIC (4.23 ± 0.01 µg/mL), ZnPc-PDT (0.002 ± 0.01 µg/mL; 20 J/cm2), and DTIC (4.23 ± 0.01 µg/mL) combined with ZnPc-PDT (0.002 ± 0.01 µg/mL; 20 J/cm2) on the expression levels of PI3K/AKT pathway-related genes at 24 h after treatment. Results are presented as mean ± SD (n = 3). One-way ANOVA test was used; * P-value < 0.05, *** P-value < 0.001, and **** P-value < 0.0001 compared to the control group.

Discussion

DTIC, as the first-line traditional therapeutic approach for melanoma in many countries, was usually administered at the bedside to treat metastatic melanoma (especially inoperable metastatic melanoma) before administering the newly approved treatments. For decades, the utilization of DTIC has been only limited to its cytotoxic effects, with disappointing clinical outcomes21. Also, many studies combining different chemotherapy drugs have been unsuccessful in increasing the clinical responses acquired with a single chemotherapeutic drug22. Nevertheless, the integration of chemotherapeutic agents with alternative anti-cancer treatments, including radiotherapy, immunotherapy, or PDT, has been acknowledged as a prospective strategy to mitigate tumor resistance through constraining tumor adaptability. Moreover, the usage of therapeutic approaches in neoadjuvant settings is gaining interest, especially for metastatic melanoma, because it can decrease the bulk of locally advanced tumors with minimal toxicities23.

Nevertheless, the integration of chemotherapeutic agents with alternative anti-cancer treatments, including radiotherapy, immunotherapy, or PDT, has been acknowledged as a prospective strategy to mitigate tumor resistance through constraining tumor adaptability. Moreover, the usage of therapeutic approaches in neoadjuvant settings is gaining interest, especially for metastatic melanoma, because it can decrease the bulk of locally advanced tumors with minimal toxicities12,24–26. The downregulation of PTEN and the following upregulation of the PI3K/AKT cascade stimulate the metastasis of melanomas triggered by activating RAS and RAF mutations. Furthermore, upregulation of PI3K/AKT is essential in primary tumor formation26. So, downregulation of this signaling pathway contributes to the prevention of tumor metastasis and may improve tumor cells’ response to traditional chemotherapies such as DTIC27.

On the other hand, upregulation of the PI3K/AKT cascade leads to phosphorylation of mTOR, which can support the cancer cell proliferation, survival, tube formation of lymphatic endothelial cells by upregulating the expression of MMP-2 and MMP-9, and migration28–31. Members of the MMP family, MMP-2 and MMP-9, are downstream targets of the PI3K/AKT cascade28.

According to our wound healing assay and qRT-PCR results, using DTIC in combination with ZnPc-PDT could strongly downregulate the gene expression levels of MMP-2, MMP-9, and cell migration ability of SK-MEL-3 cells. Also, ZnPc-PDT (alone) downregulated the expression levels of MMP-2, and MMP-9 also reduced the cell migration capability of SK-MEL-3 cells, which were more significant in the DTIC combined with ZnPc-PDT group compared to ZnPc-PDT group. However, DTIC (alone) treatment has not exhibited these inhibitory effects on the cell migration capability of SK-MEL-3 cells. Taking all the results together hitherto, combination treatment with ZnPc-PDT and DTIC has a three-pronged hopeful effect to inhibit melanoma tumor’s progression: one is increasing the sensitivity of melanoma cells towards DTIC, the other is down-regulating the PI3K/AKT pathway in SK-MEL-3 cells, and ultimately decreasing cell migration ability and metastasis by downregulation of MMP-2 and MMP-9 genes. In 2021, Huang, Bin, et al. investigated the impact of QFG (Qingjie Fuzheng Granule) on lymphangiogenesis and lymphatic metastasis in colorectal cancer (in vivo and in vitro). All results showed inhibited cell viability, invasion, migration, and tube formation of human lymphatic endothelial cells mainly through reduced MMP-9 and MMP-2 expression levels dependent PI3K/AKT pathway cascade28.

In the next step, melanoma cells’ cell cycle and apoptosis were investigated to explore the other anti-melanoma mechanisms of DTIC combined with ZnPc-PDT. In numerous cancer treatment research studies, cell cycle distribution and apoptosis level are measured to determine whether the combination treatment method, especially combination with a chemotherapy drug, is safe. If chemotherapy drugs with other treatments are combined, cell cycle arrest or apoptosis cell death occurs32.

We found that DTIC combined with ZnPc-PDT more strongly increased the number of cells in the subG1 phase of the cell cycle compared to the two studied groups separately. Furthermore, the DTIC apoptotic effect was significantly improved when melanoma cells were pre-treated with ZnPc-PDT. Flow cytometry assessment of cell cycle distribution indicated an increased subG1 cell population after all treatments. However, in line with other results obtained in this study, when the SK-MEL-3 cells were treated with a designed combination treatment, the SK-MEL-3 cell population in the subG1 phase more significantly increased compared to the two studied groups. The subG1 phase is essential in the cell cycle distribution. It is the stage in which the treated cells have fragmented DNA and enter the death processes, especially apoptosis.

To further investigate the dominant molecular mechanism of DTIC combined with ZnPc-PDT-triggered apoptosis, caspase-8, -9, and-3 expression levels were monitored by qRT-PCR. The caspases family is one of the most essential pro-apoptotic enzymes; the level of caspase-3 expression reveals the degree of apoptosis. Interestingly, the caspase-3 expression after the designed combination treatment was statistically higher than that of the DTIC or ZnPc-PDT groups. Also, combination treatment further reduced Bcl2 gene (as an anti-apoptotic gene) expression levels, which agrees with the degree of induction of apoptosis. Caspase-3 can be upregulated by both the intrinsic (mitochondrial with activation caspase-9) and extrinsic (death ligand activation caspase-8) apoptosis pathways33. The results show that DTIC combined with ZnPc-PDT of melanoma cells resulted in a more significant increase in caspase-9 and caspase-8 gene expression levels compared to a single treatment, which in turn induced the increase of caspase-3 gene expression and eventually prompted apoptosis of melanoma cells. Altogether, our results demonstrate for the first time that the DTIC combined with ZnPc-PDT triggers the anti-melanoma effects of ineffective concentrations of DTIC.

Several studies have previously investigated the combination of PDT with chemotherapeutic agents in melanoma. For instance, Doustvandi et al. (2019) demonstrated that ZnPc-PDT could enhance the efficacy of doxorubicin in melanoma cells34. However, most prior works have focused on simultaneous combination or PDT as the primary treatment modality. The present study is distinct in evaluating ZnPc-PDT as a pre-treatment sensitizer for DTIC, a first-line chemotherapeutic agent for metastatic melanoma. Our findings show that pre-treatment with sub-lethal ZnPc-PDT significantly enhances DTIC sensitivity through downregulation of the PI3K/AKT pathway, induction of apoptosis, and suppression of cell migration — effects that were less pronounced or absent when DTIC was used alone. This pre-treatment strategy represents a novel approach that may allow the use of lower, potentially less toxic doses of DTIC while achieving improved therapeutic outcomes.

Although the present study was performed in vitro, the PDT pre-treatment strategy may hold translational potential for clinical application in melanoma treatment. PDT could be administered locally to accessible lesions or lymph node metastases prior to systemic DTIC chemotherapy. The 24 h interval between PDT and DTIC used in this study might serve as an initial reference for timing; however, optimal scheduling would require further pharmacokinetic and pharmacodynamic investigations in vivo. From a dosing perspective, the application of sub-lethal PDT doses (such as IC25) appears advantageous as it may sensitize tumor cells while minimizing local toxicity. Nevertheless, several challenges remain for clinical translation, including effective delivery and penetration of ZnPc into deeper tumor tissues, standardization of light irradiation parameters in patients, potential skin photosensitivity, and heterogeneity of melanoma tumors in vivo. Despite the promising results of this study, several limitations should be acknowledged, including the use of a single melanoma cell line, reliance on in vitro experiments at a single time point (24 h), lack of protein-level validation (e.g., Western blot), and the absence of certain control groups. Future preclinical studies using multiple cell lines, Western blot analysis, multi-time point assessments, relevant control groups, as well as in vivo animal models and subsequent clinical trials, will be essential to address these limitations and fully validate the efficacy, specificity, and clinical translatability of the ZnPc-PDT pre-treatment strategy combined with DTIC.

Conclusion

In this study, we investigated the potential of ZnPc-based photodynamic therapy (PDT) as a pre-treatment to enhance the sensitivity of SK-MEL-3 melanoma cells to dacarbazine (DTIC) in vitro. Our results showed that pre-treatment with ZnPc-PDT increased DTIC sensitivity in SK-MEL-3 cells, which was associated with downregulation of the PI3K/AKT signaling pathway, induction of apoptosis, sub-G1 arrest, reduced cell migration, and decreased clonogenicity.

However, these findings are based on a single melanoma cell line and in vitro experiments conducted at a single time point (24 h). Therefore, the results should be interpreted with caution. Further in vitro and in vivo studies using multiple cell lines and animal models are necessary to validate the observed sensitizing effect and to evaluate the clinical translatability of this combination approach.

Acknowledgements

We would like to express our appreciation for the cooperation of the Clinical Research Development Unit, Imam Reza General Hospital, Tabriz, Iran, in conducting this research.

Author contributions

M.H. and M.A.D. The first author of the manuscript, performed the experiment, contributed to the cellular and molecular assays and wrote the initial version of the manuscript. F.M. Contributed to the cellular and molecular assays, analyzed the data, formal analysis and revised the manuscript. N.A.Kh., S.A.N., and S.S.S.O. Helped with the data categorization, interpreted the results and critically reviewed the manuscript. H.H., and E.M. Participate in reviewing and editing manuscript. B.B. The corresponding authors of the manuscript, supervised the project, and revised the main text of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran and the National Institute for Medical Research Development (NIMAD), Iran (project no. 4002412).

Data availability

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Declarations

Competing interests

The authors declare no competing interests.

Ethics statement

This study was ethically wise accepted by the ethics committee of Tabriz University of Medical Sciences, Tabriz, Iran (IR.TBZMED.VCR.REC.1401.230).

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Mohammad Amin Doustvandi, Email: dustvandia@tbzmed.ac.ir.

Behzad Baradaran, Email: behzad_im@yahoo.com.

References

  • 1.Li, L., London, N. R. & Chen, X. Malignant mucosal melanoma of the eustachian tube with extension into the ipsilateral external ear canal: a case report and review of the literature. Ear Nose Throat J.100 (5_suppl), 730S–733S (2021). [DOI] [PubMed] [Google Scholar]
  • 2.Yang, B. et al. MiR-5195-3p targets the PCBP2/PI3K/AKT pathway to inhibit melanoma cell proliferation and migration. Heliyon9 (9). (2023). [DOI] [PMC free article] [PubMed]
  • 3.Yde, S. S. et al. Mucosal melanoma: a literature review. Curr. Oncol. Rep.20, 1–10 (2018). [DOI] [PubMed] [Google Scholar]
  • 4.Domingues, B. et al. Melanoma treatment in review. ImmunoTargets Therapy, 35–49. (2018). [DOI] [PMC free article] [PubMed]
  • 5.Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med.377 (19), 1824–1835 (2017). [DOI] [PubMed] [Google Scholar]
  • 6.Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med.377 (14), 1345–1356 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Hell, T. et al. Flavonoids from Ericameria nauseosa inhibiting PI3K/AKT pathway in human melanoma cells. Biomed. Pharmacother.156, 113754 (2022). [DOI] [PubMed] [Google Scholar]
  • 8.Simeone, E. et al. Combination treatment of patients with BRAF-mutant melanoma: a new standard of care. BioDrugs31, 51–61 (2017). [DOI] [PubMed] [Google Scholar]
  • 9.Gide, T. N. et al. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin. Cancer Res.24 (6), 1260–1270 (2018). [DOI] [PubMed] [Google Scholar]
  • 10.Grzywa, T. M., Paskal, W. & Włodarski, P. K. Intratumor and intertumor heterogeneity in melanoma. Translational Oncol.10 (6), 956–975 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Liu, Y. & Sheikh, M. S. Melanoma: molecular pathogenesis and therapeutic management. Mol. Cell. Pharmacol.6 (3), 228 (2014). [PMC free article] [PubMed] [Google Scholar]
  • 12.Wagstaff, W. et al. Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance. Genes Dis.9 (6), 1608–1623 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Biteghe, F. N. & Davids, L. A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells. J. Photochem. Photobiol., B. 166, 18–27 (2017). [DOI] [PubMed] [Google Scholar]
  • 14.Doustvandi, M. A. et al. Photodynamic therapy with zinc phthalocyanine suppresses immune checkpoints in human melanoma cells. Lasers Med. Sci.41 (1), 78 (2026). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Doustvandi, M. A. et al. Photodynamic therapy reduced stemness and cell migration in triple-negative breast cancer cells through the PTEN/CD44 signaling pathway: A comparative study. Biochem. Biophys. Res. Commun. 153060 (2025). [DOI] [PubMed]
  • 16.Hu, J. J., Lei, Q. & Zhang, X. Z. Recent advances in photonanomedicines for enhanced cancer photodynamic therapy. Prog. Mater. Sci.114, 100685 (2020). [Google Scholar]
  • 17.Agostinis, P. et al. Photodynamic therapy of cancer: an update. Cancer J. Clin.61 (4), 250–281 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.El-Hussein, A. et al. A review of chemotherapy and photodynamic therapy for lung cancer treatment. Anti-Cancer Agents Med. Chem. (Formerly Curr. Med. Chemistry-Anti-Cancer Agents). 21 (2), 149–161 (2021). [DOI] [PubMed] [Google Scholar]
  • 19.Jiang, W. et al. The current status of photodynamic therapy in cancer treatment. Cancers15 (3), 585 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Baldea, I. & Filip, A. Photodynamic therapy in melanoma—an update. J. Physiol. Pharmacol.63 (2), 109 (2012). [PubMed] [Google Scholar]
  • 21.Chilibroste, S. et al. Preclinical evaluation of LVR01 attenuated salmonella as neoadjuvant intralesional therapy in combination with chemotherapy for melanoma treatment. J. Invest. Dermatology. 142 (5), 1435–1443 (2022). e2. [DOI] [PubMed] [Google Scholar]
  • 22.Wilson, M. A. & Schuchter, L. M. Chemotherapy for Melanoma. 209–229. (2016). [DOI] [PubMed]
  • 23.Sun, J. et al. The emergence of neoadjuvant therapy in advanced melanoma. Melanoma Manage.6 (3), MMT27 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Guo, W., Wang, H. & Li, C. Signal pathways of melanoma and targeted therapy. Signal. Transduct. Target. therapy. 6 (1), 424 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Stahl, J. M. et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res.64 (19), 7002–7010 (2004). [DOI] [PubMed] [Google Scholar]
  • 26.Zhou, X. P. et al. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol.157 (4), 1123–1128 (2000). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Sánchez-Hernández, I. et al. Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. Cancer Lett.314 (2), 244–255 (2012). [DOI] [PubMed] [Google Scholar]
  • 28.Huang, B. et al. Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway. Biomed. Pharmacother.137, 111331 (2021). [DOI] [PubMed] [Google Scholar]
  • 29.Li, H. et al. Hedyotis diffusa Willd. inhibits VEGF–C–mediated lymphangiogenesis in colorectal cancer via multiple signaling pathways. Oncol. Rep.42 (3), 1225–1236 (2019). [DOI] [PubMed] [Google Scholar]
  • 30.Tang, K. et al. Effect of honokiol on proliferation, migration and apoptosis of human tongue cancer CAL-27 cells in vitro. Nan Fang yi ke da xue xue bao=. J. South. Med. Univ.40 (4), 580–585 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Yoo, Y. A. et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res.71 (22), 7061–7070 (2011). [DOI] [PubMed] [Google Scholar]
  • 32.Zhan, X. et al. CD47-mediated DTIC-loaded chitosan oligosaccharide-grafted nGO for synergistic chemo-photothermal therapy against malignant melanoma. Mater. Sci. Engineering: C. 123, 112014 (2021). [DOI] [PubMed] [Google Scholar]
  • 33.Rajabi, N. et al. Photodynamic therapy with zinc phthalocyanine enhances the anti-cancer effect of tamoxifen in breast cancer cell line: Promising combination treatment against triple-negative breast cancer? Photodiagn. Photodyn. Ther.41, 103212 (2023). [DOI] [PubMed] [Google Scholar]
  • 34.Doustvandi, M. A. et al. Photodynamic therapy using zinc phthalocyanine with low dose of diode laser combined with doxorubicin is a synergistic combination therapy for human SK-MEL-3 melanoma cells. Photodiagn. Photodyn. Ther.28, 88–97 (2019). [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES